Most herbal medicines are orally administered and their components inevitably come into contact with intestinal microflora in the alimentary tract. These components may be transformed before they are absorbed from the gastrointestinal tract. Studies on the metabolism of herbal medicine components by human intestinal microflora are therefore of great importance in understanding their biological effects. 1, 2) Among herbal medicines, ginseng (the root of Panax ginseng C.A. MEYER, Araliaceae) is frequently used in Asian countries as a traditional medicine. The major components of ginseng are ginsenosides.
1,2)
Among herbal medicines, ginseng (the root of Panax ginseng C.A. MEYER, Araliaceae) is frequently used in Asian countries as a traditional medicine. The major components of ginseng are ginsenosides. 3, 4) These ginsenosides have been reported to show various biological activities including antiinflammatory activity 5) and antitumor effects. 6, 7) The pharmacological actions of these ginsenosides has been explained by the biotransformation of ginsenosides by human intestinal bacteria. [8] [9] [10] [11] [12] Transformed 20-O-b-D-glucopyranosyl-20(S)-protopanaxadiol (IH-901, compound K) from ginsenosides R b1 , R b2 and R c induces an antimetastatic or anticarcinogenic effect. [13] [14] [15] In addition, ginsenosides R b1 , R b2 , and R c are transformed to ginsenoside R g3 by treatment with mild acid such as stomach acid. 16) Furthermore, ginsenoside R g3 is a main component of Red Ginseng. 17) However, studies on the metabolism of ginsenoside R g3 by human intestinal bacteria are not complete.
Therefore we investigated the human intestinal bacteria capable of metabolizing ginsenoside R g3 and its related biological activities, such as in vitro cytotoxicity and anti-Helicobacter pylori (HP) activity.
MATERIALS AND METHODS

Materials and Bacterial Strains
Sodium thioglycolate and ascorbic acid were purchased from Sigma Chemical Co. (U.S.A.). General anaerobic medium (GAM) was purchased from Nissui Pharmaceutical Co., Ltd., (Japan). Tryptic soy broth was purchased from Difco Co. (U.S.A.). p-Nitrophenyl b-D-glucopyranoside (PNG) was purchased from Sigma (U.S.A.). The other chemicals were of analytical reagent grade.
Tumor cell lines were purchased from the Korean Cell Bank. HP ATCC43504 was purchased from ATCC, HP NCTC11638 was purchased from NCTC. HP82516 and HP4 clinically isolated from Korean gastroscopic samples were used. They were inoculated onto brucella agar plates supplemented with 7% horse serum and cultured for 3 days at 37°C under microaerophilic conditions (AnaeroPak Campylo: 85% N 2 , 10% CO 2 , and 5% O 2 ). Isolation of Transformants of Ginsenoside R b1 under Mild Acidic Conditions Ginsenoside R b1 (2 g) was treated in mild acidic conditions 16) at 37°C for 2 h, as previously reported, concentrated at 60°C and extracted with n-BuOH. From this BuOH fraction, 20(S)-and 20(R)-ginsenoside R g3 were isolated according to the previous method.
18 ) The BuOH fraction was chromatographed on a silica gel column using CHCl 3 -MeOH-H 2 O (10 : 3 : 1, lower layer) to produce D 20 -ginsenoside R g3 (0.05 g), and isomeric 20(S)-and 20(R)-ginsenoside R g3 (0.6 g). The isomeric mixture was dissolved in pyridine, and acetic anhydride was added drop by drop in ice bath and stirred at room temperature for 10 h. The reaction mixture was dispersed in ice water and extracted three times with EtOAc. The organic layer was washed with 5% HCl, saturated aqueous NaHCO 3 , and brine, followed by drying over anhydrous magnesium sulfate. The residue was applied to silica gel column chromatography and eluted with dichloromethane-EtOAc (8 : 1) to afford peracetylated-20(S)-ginsenoside R g3 and peracetylated-20(R)-ginsenoside R g3 . These compounds were each dissolved in 5% NaOH/nBuOH (20 ml) in an ice bath and stirred at room temperature overnight. After the reaction mixtures were washed with water and evaporated to dryness, the residues were applied to silica gel column chromatography using When ginsenoside R g3 was anaerobically incubated with human fecal microflora, all specimens metabolized ginsenoside R g3 to ginsenoside R h2 and protopanaxadiol. The main metabolite was ginsenoside R h2 . 20 Ten grams of fresh feces were suspended with 100 ml of anaerobic diluted media and centrifuged at 200ϫg for 5 min, and the precipitate was discarded. The supernatant was centrifuged at 10000ϫg for 20 min. The precipitate was washed twice with saline and used in the experiment. 
Screening of Bacteria Metabolizing Ginsenoside R g3
Among human feces tested, potent ginsenoside R g3 -hydrolyzing fresh feces were anaerobically diluted 10 3 -to 10 7 -fold. Two hundred microliters of the diluted fecal suspension were inoculated on GAM agar plates. The plates were anaerobically incubated at 37°C for 24 h. More than 100 colonies isolated from several plates, or bacteria previously isolated from human intestinal bacteria (Bacteroides HJ-15, Bacteroides JY-6, Eubacterium A-44, Bifidobacterium K-111, and Fusobacterium K-60) 13) were cultured in 50 ml of tryptic soy broth containing 0.01% sodium thioglycolate and 0.1% ascorbic acid (TSTA), and then each cultured cell was centrifuged at 3000ϫg for 10 min and washed twice with saline. The activities of these collected cells in metabolizing ginsenoside R g3 were measured using the assay method described.
Assay of Metabolic Activity of Ginsenoside R g3 by Human Intestinal Bacteria The reaction mixture containing 100 ml of 1 mM ginsenoside R g3 and 100 ml of fecal sus-pension (or bacterial suspension cultured in TSTA broth) was incubated for 12 h at 37°C. The reaction mixture was adjusted to pH 2 with HCl, extracted with ethylacetate, evaporated, and assayed by TLC: TLC plates, Silica gel 60F 254 (Merck Co., U.S.A.); developing solvent, CHCl 3 -MeOH-H 2 O (65 : 35 : 10 v/v, lower phase). The plates were stained by spraying with MeOH-H 2 SO 4 (95 : 5 v/v), followed by heating. The stained TLC plates were then analyzed using a TLC scanner (Shimadzu model CS-9301PC, Japan).
Each isolated bacterium was cultured in 50 ml of TSTA broth and centrifuged at 3000ϫg for 30 min. Each collected bacterial pellet was suspended in 50 mM phosphate buffer and used as a crude enzyme solution.
Assay of b b-Glucosidase Activity b-Glucosidase enzyme activity was assayed according to our previous method. 19) Time Course of the Metabolism of Ginsenoside R g3 by Human Fecal Microflora Ginsenoside R g3 -metabolizing activity was measured as follows. Two milliliters of fresh human fecal suspension (250 mg/ml) or the isolated intestinal bacterial suspension (250 mg/ml or 1 g/ml) were added to 8 ml of anaerobic diluted medium 11) containing 0.3 mM 20(S)-ginsenoside R g3 (or 20[R]-ginsenoside R g3 ) and then was incubated at 37°C for 1 d, and an aliquot (0.5 ml) of the reaction mixture was periodically extracted twice with 1 ml of ethylacetate. The ethylacetate fraction was analyzed by TLC. Ginsenoside R g3 and its metabolites were identified and assayed against authentic compounds isolated according to our previous method.
The fresh feces of a healthy volunteer (2 g) were collected, suspended in 48 ml of anaerobic dilution medium, centrifuged at 200ϫg and the supernatant was centrifuged at 10000ϫg for 30 min.
The isolated bacteria were cultured in 500 ml of TSTA broth and centrifuged at 10000ϫg for 30 min and washed with the anaerobic dilution medium. The fecal and bacterial precipitates (250 mg) were resuspended in 1.75 ml of anaerobic dilution medium.
Assay of Anti-HP Activity A growth inhibition assay of HP was performed according to the previous method. 19) Preparation and Assay of HP Urease The preparation of partially purified urease from HP was performed according to our previous method. 19) Urease activity was determined by the indophenol method. (Fig. 1) . The metabolic activity of 20(S)-ginsenoside R g3 to 20(S)-ginsenoside R h2 was 19-fold higher than that of 20(R)-ginsenoside R g3 to 20(R)-ginsenoside R h2 . When 20(S)-ginsenoside R g3 was incubated with human fecal microflora, it began to be transformed to 20(S)-ginsenoside R h2 , which was transformed to 20(S)-protopanaxadiol (Fig. 2) . However, 24 h after incubation the main metabolite was 20(S)-ginsenoside R h2 . The metabolic pathway of 20(R)-ginsenoside R g3 was similar to that of 20(S)-ginsenoside R g3 . However, its metabolism was weakly Fig. 1 . The Activity Transforming Ginsenoside R g3 to Ginsenoside R h2 and Protopanaxadiol by Human Fecal Microflora Human fecal suspension was prepared and its activity was assayed as described in Materials and Methods. Transforming activity of ginsenoside R g3 to ginsenoside R h2 was calculated from total transformed ginsenoside R h2 and protopanaxadiol. Symbols indicate the following: , activity transforming ginsenoside R g3 to ginsenoside R h2 ; ᮀ, activity transforming ginsenoside R g3 to protopanaxadiol.
processed.
b b-Glucosidase Activities of Human Intestinal Bacteria We cultured more than 30 bacteria isolated from human feces and measured their b-glucosidase activities to evaluate the glycoside-metabolizing activity of the bacteria isolated from human feces (Table 1) . Using PNG as a substrate, most bacteria produced potent b-glucosidase activity. These bacteria were also capable of hydrolyzing 20(S)-ginsenoside R g3 mainly giving 20(S)-ginsenoside R h2 . The most potently 20(S)-ginsenoside R g3 -hydrolyzing bacteria were Bacteroides HJ-15, Bifidobacterium K-111, Eubacterium A-44, and Fusobacterium K-60. These bacteria, except for Fusobacterium K-60, transformed 20(S)-ginsenoside R g3 to 20(S)-protopanaxdiol via 20(S)-ginsenoside R h2 (Fig. 3) . However, 20(R)-ginsenoside R g3 was hydrolyzed very little by most intestinal bacteria except for Bacteroides HJ-15 and Fusobacterium K-60. Nevertheless, these ginsenoside R g3 -transforming bacteria also hydrolyzed PNG, a synthetic substrate of bglucosidase, but PNG-hydrolyzing activity was not proportional to ginsenoside R g3 -hydrolyzing activity.
Biological Activities of Ginsenoside R g3 and Its Metabolites The inhibitory effect of ginsenoside R g3 and its metabolites on the growth of HP was measured (Table 2) . Ginsenosides R b1 , R g3 , and R h2 did not inhibit HP growth. However, 20(S)-and 20(R)-protopanaxadiols inhibited HP growth at MICs of 50-100 mg/ml. The inhibitory effects of these compounds on the activity of HP urease and H ϩ /K ϩ ATPase were also measured ( Table 3 ). Most of the tested compounds did not inhibit these enzymes. However, 20(S)-ginsenosides R g3 and R h2 weakly inhibited H ϩ /K ϩ ATPase of the rat stomach, with their IC 50 values of 0.6 and 0.48 mg/ml, respectively.
We also investigated the in vitro cytotoxic activity of ginsenoside R g3 and its metabolites on the tumor cell lines (Table 4) Han et al. reported that ginsenoside R b1 and R b2 were transformed to ginsenoside R g3 when these compounds were incubated in mildly acidic conditions, 16) and suggested that this transformation of ginsenosides R b1 and R b2 to ginsenoside R g3 could occur in the stomach. In addition, ginsenoside R g3 is a major component of Red Ginseng rather than of Ginseng. 17) When ginsenoside R g3 was incubated with human fecal microflora, it was transformed to ginsenoside R h2 and protopanaxadiol. When 20(S)-ginsenoside R g3 was incubated Table 1 with intestinal bacterial strains previously isolated, it was mainly transformed to ginsenoside R h2 . However, 20(S)-ginsenoside R g3 was potently metabolized to 20(S)-ginsenoside R h2 and 20(S)-protopanaxadiol, while 20(R)-ginsenoside R g3 was barely metabolized by the human fecal microflora and intestinal bacterial strains. Most of the isolated intestinal bacteria hydrolyzed PNG. However, some intestinal bacteria only could convert ginsenoside R g3 to protopanaxadiol via ginsenoside R h2 . This suggests that 20(S)-ginsenoside R g3 is not only a good substrate of b-glucosidase of intestinal bacteria, but is also highly soluble in water compared with 20(R)-ginsenoside R g3 .
Based on these findings, we suggest the following metabolic pathway of ginsenosides R b1 and R b2 (Chart 1). If ginsenosides R b1 and R b2 are orally administered, they could be transformed to ginsenoside R g3 in the stomach. This ginsenoside R g3 , which is in Red Ginseng as well as metabolized from ginsenosides R b1 and R b2 in the stomach, should be metabolized to ginsenoside R h2 or 20(S)-protopanaxadiol in the human intestine. However, if orally administered ginsenosides R b1 and R b2 are not transformed to ginsenoside R g3 in the stomach, they should be metabolized to IH 901 or 20(S)-protopanaxadiol in the human intestine.
To understand what the active compounds of ginsenosides and ginseng extract are when they are orally administered in humans, we measured some biological activities, anti-HP, H ϩ /K ϩ ATPase-inhibitory, and cytotoxic activity against tumor cell lines of ginsenoside R g3 and its metabolites. We Ginsenoside R b1 Ͼ100 Ͼ100 Ͼ100 Ͼ100 20(S)-Ginsenoside R g3 Ͼ100 Ͼ100 Ͼ100 Ͼ100 20(R)-Ginsenoside R g3 Ͼ100 Ͼ100 Ͼ100 Ͼ100 20(S)-Ginsenoside R h2 Ͼ100 Ͼ100 Ͼ100 Ͼ100 20(R)-Ginsenoside R h2 Ͼ100 Ͼ100 Ͼ100 Ͼ100 20(S)-Protopanaxadiol 50 50 50 50 20(R)-Protopanaxadiol 50 50 100 100 found that the cytotoxicity of ginsenosides against tumor cell lines was increased when 20(S)-ginsenoside R g3 was metabolized to 20(S)-ginsenoside R h2 or 20(S)-protopanaxdiol by human intestinal microflora. Anti-HP activity was also increased when ginsenoside R g3 was metabolized to protopanaxadiol. Furthermore, ginsenoside R h2 inhibited H ϩ /K ϩ ATPase more potently than ginsenoside R g3 . These results suggest that the natural glycosides ginsenosides R b1 and R g3 are prodrugs, which can be transformed to active compounds by intestinal microflora. Finally, we believe that 20(S)-ginsenoside R h2 and 20(S)-protopanaxadiol transformed from ginseng saponins could play an important role in the antitumor activity, and that protopanaxadiol contained in ginseng extract could inhibit HP growth, while ginsenoside R g3 cannot be transformed to protopanaxadiol in the stomach.
